.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B06A_OtherHematologicalAgents.B06AX04_Mitapivat.Mitapivat .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B06A_OtherHematologicalAgents.B06AX04_Mitapivat.Mitapivat| name: | Mitapivat | |
| ATC code: | B06AX04 | route: | oral |
| compartments: | 2 | |
| dosage: | 100 | mg |
| volume of distribution: | 44.7 | L |
| clearance: | 4.49 | L/h |
| other parameters in model implementation | ||
Mitapivat is a first-in-class, oral pyruvate kinase activator used in the treatment of hemolytic anemia in adults with pyruvate kinase deficiency. It is an approved drug, notably by the FDA and EMA.
Pharmacokinetic parameters observed following single and multiple oral doses in healthy adult volunteers, both male and female.